{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:24:48Z","timestamp":1790270688182,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bispecific antibody recruiters (BARs) are an innovative class of immunotherapeutics that redirect endogenous antibodies to tumor cells. BARs comprise a tumor-binding and an antibody-binding module, enabling endogenous antibodies to opsonize tumor cells and induce F\n                    <jats:sub>C<\/jats:sub>\n                    -dependent effector functions such as complement-dependent cytotoxicity (CDC). CD38 is a validated target for myeloma therapy, as evidenced by the success of CD38-specific monoclonal antibodies daratumumab and isatuximab. Nanobodies are single variable immunoglobulin domains derived from camelid heavy chain antibodies. Here, we report the generation of nanobody-based BARs recognizing CD38 and assess their cytotoxicity against CD38-expressing myeloma cells in vitro and ex vivo. We constructed three CD38-specific BARs recognizing distinct, non-overlapping CD38 epitopes (E1-BAR, E2-BAR, and E3-BAR) by genetically fusing CD38-specific nanobodies to a human immunoglobulin \u03ba light chain-specific nanobody. All BARs exhibited simultaneous binding to CD38 and IgG\u03ba. Nonlinear regression revealed EC\n                    <jats:sub>50<\/jats:sub>\n                    values of 0.73\u00a0nM (E1-BAR), 0.21\u00a0nM (E2-BAR), and 0.97\u00a0nM (E3-BAR). In patient-derived myeloma cells, E1-BAR reduced viability to 29\u2009\u00b1\u200918%, while E2-BAR and E3-BAR achieved 62\u2009\u00b1\u200949% and 57\u2009\u00b1\u200941%, respectively. In vivo, BAR half-life was markedly increased by IgG\u03ba binding. Our results demonstrate the feasibility of CD38-specific nanobody-based BARs as therapeutics for multiple myeloma.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-25194-y","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:18:34Z","timestamp":1763464714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-7833","authenticated-orcid":false,"given":"Luca Julius","family":"Pape","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5350-8911","authenticated-orcid":false,"given":"Anna Josephine","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten","family":"Dannenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Risch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Duttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0305-5850","authenticated-orcid":false,"given":"Julia","family":"Hambach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-6674","authenticated-orcid":false,"given":"Friedrich","family":"Koch-Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-534X","authenticated-orcid":false,"given":"Peter","family":"Bannas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"25194_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard, F. et al. Multiple myeloma. Nat. Rev. Dis. Primers. 10, 45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7 (2024).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"25194_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou, L. et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer 21, 606. https:\/\/doi.org\/10.1186\/s12885-021-08280-y (2021).","journal-title":"BMC Cancer"},{"key":"25194_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Pawlyn, C. & Yong, K. L. Multiple myeloma. The Lancet. 397, 410\u2013427. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5 (2021).","journal-title":"The Lancet."},{"key":"25194_CR4","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau, P. et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 22, e105\u2013e118. https:\/\/doi.org\/10.1016\/S1470-2045(20)30756-7 (2021).","journal-title":"Lancet Oncol."},{"key":"25194_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020). Ann. Oncol. 32, 309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014 (2021).","journal-title":"Ann. Oncol."},{"key":"25194_CR6","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99, 1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27422 (2024).","journal-title":"Am. J. Hematol."},{"key":"25194_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. Bispecific antibodies: A mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"25194_CR8","doi-asserted-by":"publisher","first-page":"2310890","DOI":"10.1080\/19420862.2024.2310890","volume":"16","author":"DL Niquille","year":"2024","unstructured":"Niquille, D. L., Fitzgerald, K. M. & Gera, N. Biparatopic antibodies: Therapeutic applications and prospects. MAbs 16, 2310890. https:\/\/doi.org\/10.1080\/19420862.2024.2310890 (2024).","journal-title":"MAbs"},{"key":"25194_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J. & Germeraad, W. T. V. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J. Hematol. Oncol. 14, 73. https:\/\/doi.org\/10.1186\/s13045-021-01083-5 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"25194_CR10","doi-asserted-by":"publisher","unstructured":"Parikh, R. H., Lonial, S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA Cancer J. Clin. 73, 275\u2013285 (2023). https:\/\/doi.org\/10.3322\/caac.21771","DOI":"10.3322\/caac.21771"},{"key":"25194_CR11","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ajh.26628","volume":"98","author":"G Ravi","year":"2023","unstructured":"Ravi, G. & Costa, L. J. Bispecific T-cell engagers for treatment of multiple myeloma. Am. J. Hematol. 98, S13\u2013S21. https:\/\/doi.org\/10.1002\/ajh.26628 (2023).","journal-title":"Am. J. Hematol."},{"key":"25194_CR12","doi-asserted-by":"publisher","first-page":"1207276","DOI":"10.3389\/fimmu.2023.1207276","volume":"14","author":"M Zhang","year":"2023","unstructured":"Zhang, M., Lam, K. P. & Xu, S. Natural killer cell engagers (NKCEs): A new frontier in cancer immunotherapy. Front. Immunol. 14, 1207276. https:\/\/doi.org\/10.3389\/fimmu.2023.1207276 (2023).","journal-title":"Front. Immunol."},{"key":"25194_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1021\/cb300119g","volume":"7","author":"PJ McEnaney","year":"2012","unstructured":"McEnaney, P. J., Parker, C. G., Zhang, A. X. & Spiegel, D. A. Antibody-recruiting molecules: An emerging paradigm for engaging immune function in treating human disease. ACS Chem. Biol. 7, 1139\u20131151. https:\/\/doi.org\/10.1021\/cb300119g (2012).","journal-title":"ACS Chem. Biol."},{"key":"25194_CR14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1039\/d1cb00007a","volume":"2","author":"S Achilli","year":"2021","unstructured":"Achilli, S., Berthet, N. & Renaudet, O. Antibody recruiting molecules (ARMs): Synthetic immunotherapeutics to fight cancer. RSC Chem. Biol. 2, 713\u2013724. https:\/\/doi.org\/10.1039\/d1cb00007a (2021).","journal-title":"RSC Chem. Biol."},{"key":"25194_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nbt0797-632","volume":"15","author":"P Holliger","year":"1997","unstructured":"Holliger, P., Wing, M., Pound, J. D., Bohlen, H. & Winter, G. Retargeting serum immunoglobulin with bispecific diabodies. Nat. Biotechnol. 15, 632\u2013636. https:\/\/doi.org\/10.1038\/nbt0797-632 (1997).","journal-title":"Nat. Biotechnol."},{"key":"25194_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202303909","volume":"35","author":"A Uvyn","year":"2023","unstructured":"Uvyn, A. et al. Hapten\/myristoyl functionalized poly(propyleneimine) dendrimers as potent cell surface recruiters of antibodies for mediating innate immune killing. Adv. Mater. 35, e2303909. https:\/\/doi.org\/10.1002\/adma.202303909 (2023).","journal-title":"Adv. Mater."},{"key":"25194_CR17","doi-asserted-by":"publisher","unstructured":"Liu, X., Balligand, T., Carpenet, C. & Ploegh, H. L. An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections. Sci. Immunol. 8, eadg9459 (2023). https:\/\/doi.org\/10.1126\/sciimmunol.adg9459","DOI":"10.1126\/sciimmunol.adg9459"},{"key":"25194_CR18","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1039\/d0sc05332e","volume":"12","author":"H Hong","year":"2021","unstructured":"Hong, H. et al. Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy. Chem. Sci. 12, 4623\u20134630. https:\/\/doi.org\/10.1039\/d0sc05332e (2021).","journal-title":"Chem. Sci."},{"key":"25194_CR19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","volume":"8","author":"P Bannas","year":"2017","unstructured":"Bannas, P., Hambach, J. & Koch-Nolte, F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front. Immunol. 8, 1603. https:\/\/doi.org\/10.3389\/fimmu.2017.01603 (2017).","journal-title":"Front. Immunol."},{"key":"25194_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: Natural single-domain antibodies. Annu. Rev. Biochem. 82, 775\u2013797. https:\/\/doi.org\/10.1146\/annurev-biochem-063011-092449 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"25194_CR21","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1021\/bi011239a","volume":"41","author":"S Ewert","year":"2002","unstructured":"Ewert, S., Cambillau, C., Conrath, K. & Pl\u00fcckthun, A. Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry 41, 3628\u20133636. https:\/\/doi.org\/10.1021\/bi011239a (2002).","journal-title":"Biochemistry"},{"key":"25194_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baad021","author":"MS Vald\u00e9s-Tresanco","year":"2023","unstructured":"Vald\u00e9s-Tresanco, M. S., Vald\u00e9s-Tresanco, M. E., Molina-Abad, E. & Moreno, E. NbThermo: A new thermostability database for nanobodies. Database https:\/\/doi.org\/10.1093\/database\/baad021 (2023).","journal-title":"Database"},{"key":"25194_CR23","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1038\/s41598-018-26338-z","volume":"8","author":"P Kunz","year":"2018","unstructured":"Kunz, P. et al. The structural basis of nanobody unfolding reversibility and thermoresistance. Sci. Rep. 8, 7934. https:\/\/doi.org\/10.1038\/s41598-018-26338-z (2018).","journal-title":"Sci. Rep."},{"key":"25194_CR24","doi-asserted-by":"publisher","first-page":"1005800","DOI":"10.3389\/fimmu.2022.1005800","volume":"13","author":"J Hambach","year":"2022","unstructured":"Hambach, J., Mann, A. M., Bannas, P. & Koch-Nolte, F. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. Front. Immunol. 13, 1005800. https:\/\/doi.org\/10.3389\/fimmu.2022.1005800 (2022).","journal-title":"Front. Immunol."},{"key":"25194_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040058","author":"J Golay","year":"2020","unstructured":"Golay, J. & Taylor, R. P. The role of complement in the mechanism of action of therapeutic anti-cancer mAbs. Antibodies (Basel) https:\/\/doi.org\/10.3390\/antib9040058 (2020).","journal-title":"Antibodies (Basel)"},{"key":"25194_CR26","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343, 1260\u20131263. https:\/\/doi.org\/10.1126\/science.1248943 (2014).","journal-title":"Science"},{"key":"25194_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002344","volume":"14","author":"RN de Jong","year":"2016","unstructured":"de Jong, R. N. et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 14, e1002344. https:\/\/doi.org\/10.1371\/journal.pbio.1002344 (2016).","journal-title":"PLoS Biol."},{"key":"25194_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof, I. S. et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood 128, 959\u2013970. https:\/\/doi.org\/10.1182\/blood-2016-03-703439 (2016).","journal-title":"Blood"},{"key":"25194_CR29","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers, M. et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186, 1840\u20131848. https:\/\/doi.org\/10.4049\/jimmunol.1003032 (2011).","journal-title":"J. Immunol."},{"key":"25194_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NWCJ van de Donk","year":"2016","unstructured":"van de Donk, N. W. C. J. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Rev. 270, 95\u2013112. https:\/\/doi.org\/10.1111\/imr.12389 (2016).","journal-title":"Immunol. Rev."},{"key":"25194_CR31","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.3324\/haematol.2017.169235","volume":"102","author":"A Oberle","year":"2017","unstructured":"Oberle, A. et al. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. Haematologica 102, e368\u2013e370. https:\/\/doi.org\/10.3324\/haematol.2017.169235 (2017).","journal-title":"Haematologica"},{"key":"25194_CR32","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/s2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 7, e370\u2013e380. https:\/\/doi.org\/10.1016\/s2352-3026(20)30070-3 (2020).","journal-title":"Lancet Haematol."},{"key":"25194_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104663","volume":"93","author":"IH Hiemstra","year":"2023","unstructured":"Hiemstra, I. H. et al. Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. EBioMedicine 93, 104663. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104663 (2023).","journal-title":"EBioMedicine"},{"key":"25194_CR34","doi-asserted-by":"publisher","first-page":"15508","DOI":"10.1002\/chem.201903327","volume":"25","author":"B Liet","year":"2019","unstructured":"Liet, B. et al. Multifunctional glycoconjugates for recruiting natural antibodies against cancer cells. Chem. A Eur. J. 25, 15508\u201315515. https:\/\/doi.org\/10.1002\/chem.201903327 (2019).","journal-title":"Chem. A Eur. J."},{"key":"25194_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1021\/acs.biomac.9b01483","volume":"21","author":"R De Coen","year":"2020","unstructured":"De Coen, R. et al. Synthetic rhamnose glycopolymer cell-surface receptor for endogenous antibody recruitment. Biomacromol 21, 793\u2013802. https:\/\/doi.org\/10.1021\/acs.biomac.9b01483 (2020).","journal-title":"Biomacromol"},{"key":"25194_CR36","doi-asserted-by":"publisher","unstructured":"Hong, H. et al. Chemoenzymatic synthesis of a rhamnose-functionalized bispecific nanobody as a bispecific antibody mimic for cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 61: e202208773 (2022). https:\/\/doi.org\/10.1002\/anie.202208773","DOI":"10.1002\/anie.202208773"},{"key":"25194_CR37","doi-asserted-by":"publisher","unstructured":"Li, Y. et al. Multivalent rhamnose-modified EGFR-targeting nanobody gains enhanced innate fc effector immunity and overcomes cetuximab resistance via recruitment of endogenous antibodies. Adv. Sci. (Weinh). 11: e2307613 (2024). https:\/\/doi.org\/10.1002\/advs.202307613","DOI":"10.1002\/advs.202307613"},{"key":"25194_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2024.11.080","volume":"378","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Reconstituting the immune killing functions and improving the pharmacokinetics of nanobodies by rhamnolipid conjugation. J. Control Release 378, 18\u201326. https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.080 (2025).","journal-title":"J. Control Release"},{"key":"25194_CR39","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1002\/anie.201510866","volume":"55","author":"AF Rullo","year":"2016","unstructured":"Rullo, A. F. et al. Re-engineering the immune response to metastatic cancer: antibody-recruiting small molecules targeting the urokinase receptor. Angew Chem. Int. Ed. Engl. 55, 3642\u20133646. https:\/\/doi.org\/10.1002\/anie.201510866 (2016).","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"25194_CR40","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1038\/s41467-018-05566-x","volume":"9","author":"B Schrand","year":"2018","unstructured":"Schrand, B. et al. Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity. Nat. Commun. 9, 3348. https:\/\/doi.org\/10.1038\/s41467-018-05566-x (2018).","journal-title":"Nat. Commun."},{"key":"25194_CR41","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1021\/acschembio.0c00112","volume":"15","author":"B Lake","year":"2020","unstructured":"Lake, B., Serniuck, N., Kapcan, E., Wang, A. & Rullo, A. F. Covalent immune recruiters: Tools to gain chemical control over immune recognition. ACS Chem. Biol. 15, 1089\u20131095. https:\/\/doi.org\/10.1021\/acschembio.0c00112 (2020).","journal-title":"ACS Chem. Biol."},{"key":"25194_CR42","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1039\/d3sc01507f","volume":"14","author":"R Aksakal","year":"2023","unstructured":"Aksakal, R. et al. Sequence-defined antibody-recruiting macromolecules. Chem. Sci. 14, 6572\u20136578. https:\/\/doi.org\/10.1039\/d3sc01507f (2023).","journal-title":"Chem. Sci."},{"key":"25194_CR43","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1002\/cmdc.202100313","volume":"16","author":"H Lin","year":"2021","unstructured":"Lin, H. et al. Dinitrophenol-hyaluronan conjugates as multivalent antibody-recruiting glycopolymers for targeted cancer immunotherapy. ChemMedChem 16, 2960\u20132968. https:\/\/doi.org\/10.1002\/cmdc.202100313 (2021).","journal-title":"ChemMedChem"},{"key":"25194_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/antib9020022","author":"S Boune","year":"2020","unstructured":"Boune, S., Hu, P., Epstein, A. L. & Khawli, L. A. Principles of N-linked glycosylation variations of IgG-based therapeutics: Pharmacokinetic and functional considerations. Antibodies (Basel). https:\/\/doi.org\/10.3390\/antib9020022 (2020).","journal-title":"Antibodies (Basel)."},{"key":"25194_CR45","doi-asserted-by":"crossref","unstructured":"Nimmerjahn, F. & Werner, A. Sweet rules: Linking glycosylation to antibody function. (ed. Pezer, M.) Antibody Glycosylation 365\u2013393 (Springer International Publishing, 2021).","DOI":"10.1007\/978-3-030-76912-3_12"},{"key":"25194_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/cei.13545","volume":"203","author":"N Vukovic","year":"2021","unstructured":"Vukovic, N., van Elsas, A., Verbeek, J. S. & Zaiss, D. M. W. Isotype selection for antibody-based cancer therapy. Clin. Exp. Immunol. 203, 351\u2013365. https:\/\/doi.org\/10.1111\/cei.13545 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"25194_CR47","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","volume":"113","author":"P Bruhns","year":"2009","unstructured":"Bruhns, P. et al. Specificity and affinity of human Fc\u03b3 receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716\u20133725. https:\/\/doi.org\/10.1182\/blood-2008-09-179754 (2009).","journal-title":"Blood"},{"key":"25194_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2162-3619-1-9","volume":"1","author":"E Koulieris","year":"2012","unstructured":"Koulieris, E. et al. Ratio of involved\/uninvolved immunoglobulin quantification by Hevylite\u2122 assay: Clinical and prognostic impact in multiple myeloma. Exp. Hematol. Oncol. 1, 9. https:\/\/doi.org\/10.1186\/2162-3619-1-9 (2012).","journal-title":"Exp. Hematol. Oncol."},{"key":"25194_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10409238.2019.1659227","volume":"54","author":"K Yu","year":"2019","unstructured":"Yu, K. & Lieber, M. R. Current insights into the mechanism of mammalian immunoglobulin class switch recombination. Crit. Rev. Biochem. Mol. Biol. 54, 333\u2013351. https:\/\/doi.org\/10.1080\/10409238.2019.1659227 (2019).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"25194_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247847","volume":"16","author":"LM Slot","year":"2021","unstructured":"Slot, L. M. et al. Light chain skewing in autoantibodies and B-cell receptors of the citrullinated antigen-binding B-cell response in rheumatoid arthritis. PLoS ONE 16, e0247847. https:\/\/doi.org\/10.1371\/journal.pone.0247847 (2021).","journal-title":"PLoS ONE"},{"key":"25194_CR51","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/jco.2010.29.4413","volume":"29","author":"MJ Maurer","year":"2011","unstructured":"Maurer, M. J. et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 29, 1620\u20131626. https:\/\/doi.org\/10.1200\/jco.2010.29.4413 (2011).","journal-title":"J. Clin. Oncol."},{"key":"25194_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4049\/jimmunol.2200952","volume":"211","author":"DV Pedersen","year":"2023","unstructured":"Pedersen, D. V. et al. Bispecific complement engagers for targeted complement activation. J. Immunol. 211, 403\u2013413. https:\/\/doi.org\/10.4049\/jimmunol.2200952 (2023).","journal-title":"J. Immunol."},{"key":"25194_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nri.2017.97","volume":"18","author":"ES Reis","year":"2018","unstructured":"Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A. & Lambris, J. D. Complement in cancer: untangling an intricate relationship. Nat. Rev. Immunol. 18, 5\u201318. https:\/\/doi.org\/10.1038\/nri.2017.97 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"25194_CR54","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1172\/JCI90962","volume":"127","author":"V Afshar-Kharghan","year":"2017","unstructured":"Afshar-Kharghan, V. The role of the complement system in cancer. J. Clin. Investig. 127, 780\u2013789. https:\/\/doi.org\/10.1172\/JCI90962 (2017).","journal-title":"J. Clin. Investig."},{"key":"25194_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2014.146","volume":"29","author":"O Middleton","year":"2015","unstructured":"Middleton, O. et al. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL. Leukemia 29, 107\u2013114. https:\/\/doi.org\/10.1038\/leu.2014.146 (2015).","journal-title":"Leukemia"},{"key":"25194_CR56","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","volume":"22","author":"RE Kontermann","year":"2011","unstructured":"Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 22, 868\u2013876. https:\/\/doi.org\/10.1016\/j.copbio.2011.06.012 (2011).","journal-title":"Curr. Opin. Biotechnol."},{"key":"25194_CR57","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/cmmi.1637","volume":"10","author":"P Bannas","year":"2015","unstructured":"Bannas, P. et al. Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection. Contrast Media Mol Imaging. 10, 367\u2013378. https:\/\/doi.org\/10.1002\/cmmi.1637 (2015).","journal-title":"Contrast Media Mol Imaging."},{"key":"25194_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cmmi.1548","volume":"9","author":"P Bannas","year":"2014","unstructured":"Bannas, P. et al. In vivo near-infrared fluorescence targeting of T cells: Comparison of nanobodies and conventional monoclonal antibodies. Contrast Media Mol. Imaging 9, 135\u2013142. https:\/\/doi.org\/10.1002\/cmmi.1548 (2014).","journal-title":"Contrast Media Mol. Imaging"},{"key":"25194_CR59","doi-asserted-by":"publisher","DOI":"10.3791\/52462","author":"P Bannas","year":"2015","unstructured":"Bannas, P. et al. Validation of nanobody and antibody based in vivo tumor xenograft NIRF-imaging experiments in mice using ex vivo flow cytometry and microscopy. J. Vis. Exp. https:\/\/doi.org\/10.3791\/52462 (2015).","journal-title":"J. Vis. Exp."},{"key":"25194_CR60","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1039\/d0sc00017e","volume":"11","author":"K Sasaki","year":"2020","unstructured":"Sasaki, K. et al. Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses. Chem. Sci. 11, 3208\u20133214. https:\/\/doi.org\/10.1039\/d0sc00017e (2020).","journal-title":"Chem. Sci."},{"key":"25194_CR61","doi-asserted-by":"publisher","first-page":"1010270","DOI":"10.3389\/fimmu.2022.1010270","volume":"13","author":"LJ Pape","year":"2022","unstructured":"Pape, L. J. et al. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy. Front. Immunol. 13, 1010270. https:\/\/doi.org\/10.3389\/fimmu.2022.1010270 (2022).","journal-title":"Front. Immunol."},{"key":"25194_CR62","doi-asserted-by":"publisher","first-page":"14289","DOI":"10.1038\/s41598-017-14112-6","volume":"7","author":"W Fumey","year":"2017","unstructured":"Fumey, W. et al. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo. Sci. Rep. 7, 14289. https:\/\/doi.org\/10.1038\/s41598-017-14112-6 (2017).","journal-title":"Sci. Rep."},{"key":"25194_CR63","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study. The Lancet. 398, 314\u2013324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8 (2021).","journal-title":"The Lancet."},{"key":"25194_CR64","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/jco.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274. https:\/\/doi.org\/10.1200\/jco.22.00842 (2023).","journal-title":"J. Clin. Oncol."},{"key":"25194_CR65","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"W-H Zhao","year":"2018","unstructured":"Zhao, W.-H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11, 141. https:\/\/doi.org\/10.1186\/s13045-018-0681-6 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"25194_CR66","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.7150\/thno.38533","volume":"10","author":"L Schriewer","year":"2020","unstructured":"Schriewer, L. et al. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Theranostics. 10, 2645\u20132658. https:\/\/doi.org\/10.7150\/thno.38533 (2020).","journal-title":"Theranostics."},{"key":"25194_CR67","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/gt.2009.149","volume":"17","author":"K Weber","year":"2010","unstructured":"Weber, K., Mock, U., Petrowitz, B., Bartsch, U. & Fehse, B. Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: New building blocks for cell marking and multi-gene analysis. Gene Ther. 17, 511\u2013520. https:\/\/doi.org\/10.1038\/gt.2009.149 (2010).","journal-title":"Gene Ther."},{"key":"25194_CR68","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4161\/mabs.25077","volume":"5","author":"B Cl\u00e9menceau","year":"2013","unstructured":"Cl\u00e9menceau, B. et al. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential. MAbs 5, 587\u2013594. https:\/\/doi.org\/10.4161\/mabs.25077 (2013).","journal-title":"MAbs"},{"key":"25194_CR69","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cellimm.2005.08.033","volume":"236","author":"F Koch-Nolte","year":"2005","unstructured":"Koch-Nolte, F. et al. Use of genetic immunization to raise antibodies recognizing toxin-related cell surface ADP-ribosyltransferases in native conformation. Cell. Immunol. 236, 66\u201371. https:\/\/doi.org\/10.1016\/j.cellimm.2005.08.033 (2005).","journal-title":"Cell. Immunol."},{"key":"25194_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02553","author":"K Sch\u00fctze","year":"2018","unstructured":"Sch\u00fctze, K. et al. CD38-specific biparatopic heavy chain antibodies display potent complement-dependent cytotoxicity against multiple myeloma cells. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.02553 (2018).","journal-title":"Front. Immunol."},{"key":"25194_CR71","doi-asserted-by":"publisher","first-page":"7850","DOI":"10.1038\/srep07850","volume":"5","author":"M Unger","year":"2015","unstructured":"Unger, M. et al. Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT. Sci. Rep. 5, 7850. https:\/\/doi.org\/10.1038\/srep07850 (2015).","journal-title":"Sci. Rep."},{"key":"25194_CR72","unstructured":"Hermanns, W., Josephus, J., Ten Haaft, M. R., Overweel, A. Method for affinity purification. In: Organization, W. I. P. ed. C07K 16\/06 ed: Unilever N.V.; 2006: 58."},{"key":"25194_CR73","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","volume":"65","author":"X Chen","year":"2013","unstructured":"Chen, X., Zaro, J. L. & Shen, W. C. Fusion protein linkers: Property, design and functionality. Adv. Drug Deliv. Rev. 65, 1357\u20131369. https:\/\/doi.org\/10.1016\/j.addr.2012.09.039 (2013).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"25194_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032914","author":"IP S\u00e6b\u00f8","year":"2023","unstructured":"S\u00e6b\u00f8, I. P., Bj\u00f8r\u00e5s, M., Franzyk, H., Helgesen, E. & Booth, J. A. Optimization of the hemolysis assay for the assessment of cytotoxicity. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24032914 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"25194_CR75","doi-asserted-by":"crossref","unstructured":"Lim, E. W. K., Brolin, C. & Nielsen, P. E. Near-infrared in vivo whole-body fluorescence imaging of PNA. (ed. Nielsen, P. E.) Peptide Nucleic Acids: Methods and Protocols 251\u2013260 (Springer US, 2020).","DOI":"10.1007\/978-1-0716-0243-0_16"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25194-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25194-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25194-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:07:46Z","timestamp":1781615266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25194-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25194"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25194-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FK-N receives a share of antibody sales via MediGate GmbH, a wholly-owned subsidiary of University Medical Center Hamburg-Eppendorf. PB and FK-N are co-inventors on a patent application on CD38-specific nanobodies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40376"}}